Therefore, our computational analysis provided quantitative evidence that PDGF:VEGFR2, cross-family binding should significantly participate in VEGFR2 ligation under conditions of health physiology, breast cancer, and pathologies where PDGFs significantly outnumber VEGFs. The gene discussed is KDR; the disease is breast carcinoma.